[go: up one dir, main page]

MX2012013589A - Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk). - Google Patents

Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk).

Info

Publication number
MX2012013589A
MX2012013589A MX2012013589A MX2012013589A MX2012013589A MX 2012013589 A MX2012013589 A MX 2012013589A MX 2012013589 A MX2012013589 A MX 2012013589A MX 2012013589 A MX2012013589 A MX 2012013589A MX 2012013589 A MX2012013589 A MX 2012013589A
Authority
MX
Mexico
Prior art keywords
jnk
inhibitors
amino
pyrimidine derivatives
derivatives useful
Prior art date
Application number
MX2012013589A
Other languages
English (en)
Inventor
David Mark Rotstein
David Michael Goldstein
Wylie Solang Palmer
Leyi Gong
Tania Silva
Yun-Chou Tan
Humberto Bartolome Arzeno
Bradley E Loe
Lubov Filonova
Erin M O'brien
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012013589A publication Critical patent/MX2012013589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la Fórmula I o sales farmacéuticamente aceptable de los mismos, en donde R5 es un grupo de la Fórmula (a) o (b); y en donde m, n, p, q, X, Y, R1, R2, R3, R4, R5, R6, R7, R8, y R9 son como se definió aquí. Los compuestos y composiciones descritos aquí son útiles para modular la actividad de JNK y tratar enfermedades asociadas con actividad de JNK.
MX2012013589A 2010-06-04 2011-06-01 Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk). MX2012013589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35165210P 2010-06-04 2010-06-04
PCT/EP2011/059005 WO2011151358A1 (en) 2010-06-04 2011-06-01 2 -amino- pyrimidine derivatives useful as inhibitors of jnk

Publications (1)

Publication Number Publication Date
MX2012013589A true MX2012013589A (es) 2012-12-17

Family

ID=44201987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013589A MX2012013589A (es) 2010-06-04 2011-06-01 Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk).

Country Status (11)

Country Link
US (1) US8642601B2 (es)
EP (1) EP2576537B1 (es)
JP (1) JP5916719B2 (es)
KR (1) KR101800916B1 (es)
CN (1) CN102918035B (es)
BR (1) BR112012030931A2 (es)
CA (1) CA2799328C (es)
ES (1) ES2567828T3 (es)
MX (1) MX2012013589A (es)
RU (1) RU2572247C2 (es)
WO (1) WO2011151358A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104036185B (zh) * 2014-06-23 2017-04-12 常熟理工学院 基于虚拟化的宏内核操作系统载入模块权能隔离方法
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
CN113956240B (zh) * 2021-11-03 2023-02-14 陕西师范大学 一类嘧啶衍生物及其制备抗肿瘤药物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091249A1 (en) * 2002-04-25 2003-11-06 Applied Research Systems Ars Holding N.V. Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
CN101511359B (zh) * 2006-09-08 2012-09-05 霍夫曼-拉罗奇有限公司 苯并三唑激酶调节剂
BRPI0720003A2 (pt) * 2006-12-08 2018-09-18 Hoffmann La Roche pirimidinas substituídas e seu uso como moduladores de jnk
ES2392788T3 (es) * 2008-05-16 2012-12-13 F. Hoffmann-La Roche Ag Inhibidores de las JNK

Also Published As

Publication number Publication date
WO2011151358A1 (en) 2011-12-08
ES2567828T3 (es) 2016-04-26
CN102918035B (zh) 2015-05-27
US8642601B2 (en) 2014-02-04
CA2799328C (en) 2018-02-20
KR101800916B1 (ko) 2017-11-23
KR20130085406A (ko) 2013-07-29
JP5916719B2 (ja) 2016-05-11
EP2576537B1 (en) 2016-03-16
HK1177931A1 (en) 2013-08-30
CN102918035A (zh) 2013-02-06
EP2576537A1 (en) 2013-04-10
CA2799328A1 (en) 2011-12-08
JP2013527215A (ja) 2013-06-27
US20110301171A1 (en) 2011-12-08
BR112012030931A2 (pt) 2016-11-08
RU2572247C2 (ru) 2016-01-10
RU2012155143A (ru) 2014-07-20

Similar Documents

Publication Publication Date Title
PH12017501192A1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
MY163498A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
CA2875877C (en) Syk inhibitors
PH12017501326A1 (en) Tgf-� inhibitors
MY162535A (en) Inhibitors of arginase and their therapeutic applications
PH12012501546A1 (en) Substituted pyrrolidine-2-carboxamides
MX338707B (es) Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos.
PH12014501417A1 (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
TN2011000400A1 (en) Inhibitors of beta-secretase
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
IN2014DN07509A (es)
MX344911B (es) Compuestos de eter amido-piridilico y composiciones y su uso contra parasitos.
MX390763B (es) Compuestos de tetraciclina
MX355561B (es) Proceso para hacer inhibidores de girasa y topoisomerasa iv.
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX2012013589A (es) Derivados de 2-amino pirimidina utiles como inhibidores de cinasas del extremo n-terminal de c-jun (jnk).
MX2013005825A (es) Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion.
IN2014CN04922A (es)
MX358151B (es) Derivado de sitaxentan.
UA111150C2 (uk) Гетероциклічна сполука як інгібітор циклу поділу клітини 7, лікарський засіб, що її містить, її застосування та спосіб інгібування циклу клітинного поділу 7 та профілактики або лікування раку у ссавця

Legal Events

Date Code Title Description
FG Grant or registration